Concepedia

David Gonzales

DG

Statistics

Publications

19

Citations

3.6K

H-Index

19

Active since

1995

Affiliations

Oregon Health & Science University(Current)

Massachusetts General Hospital

Research Triangle Park Foundation

Oregon National Primate Research Center

Indiana University – Purdue University Indianapolis

David Gonzales is an author at Oregon Health & Science University specializing in smoking cessation, tobacco use cessation, and tobacco cessation.

ORCID

Publications per year

1995–2022

19

Publications

19

Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

David Gonzales · JAMA · 2006 · 1.4K citations

, , +17

Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial

DP Tashkin, Richard E. Kanner, William C. Bailey et al. · The Lancet · 2001 · 416 citations

, , +10

Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation

J. Taylor Hays, R. Douglas Hurt, Nancy A. Rigotti et al. · Annals of Internal Medicine · 2001 · 339 citations

, , +17

Vitamin C Supplementation for Pregnant Smoking Women and Pulmonary Function in Their Newborn Infants

Cindy T. McEvoy, Diane Schilling, Nakia Clay et al. · JAMA · 2014 · 223 citations · Full text

, , +16

Immunogenicity and Smoking-Cessation Outcomes for a Novel Nicotine Immunotherapeutic

Dorothy K. Hatsukami, Douglas E. Jorenby, David Gonzales et al. · Clinical Pharmacology & Therapeutics · 2011 · 185 citations · Full text

, , +17

1–5 of 19